Overview
Liraglutide was Novo Nordisk’s first long-acting GLP-1 receptor agonist and the commercial predecessor to semaglutide. Approved as Victoza for type 2 diabetes in 2010, it became Saxenda (at higher dose) for obesity management in 2014 — marking the first time a GLP-1 agonist received approval specifically for weight management.
Though largely supplanted by semaglutide in prescribing practice (due to less frequent dosing and greater efficacy), liraglutide represented a landmark in metabolic medicine and established the clinical proof-of-concept for the GLP-1 class in cardiovascular risk reduction (LEADER trial, 2016).
Mechanism of Action
Liraglutide has 97% amino acid sequence homology with human GLP-1, modified with a C16 fatty acid chain (via a linker) enabling albumin binding and extending half-life from minutes (native GLP-1) to ~13 hours. This allows once-daily dosing.
Actions mirror the GLP-1 class:
- Glucose-dependent insulin secretion
- Glucagon suppression
- Gastric emptying delay (satiety prolongation)
- Hypothalamic appetite suppression
- Direct cardiovascular effects (GLP-1R on cardiomyocytes)
Clinical Research & Evidence
Evidence Level: 🟢 EL1 — Multiple Phase III RCTs, FDA approved
| Trial | N | Key Finding |
|---|---|---|
| LEADER | 9,340 | 13% reduction in MACE (CV death, MI, stroke) vs. placebo in T2DM |
| SCALE Obesity | 3,731 | 8.4% mean weight loss at 3.0 mg vs. 2.8% placebo (56 weeks) |
| SCALE Maintenance | 422 | Maintained weight loss vs. placebo after diet-induced weight loss |
FDA-Approved Indications
- Victoza (1.2–1.8 mg/day): Type 2 diabetes + CV risk reduction in T2DM with CVD
- Saxenda (3.0 mg/day): Chronic weight management — adults BMI ≥30, or ≥27 with comorbidity; adolescents 12+ years, BMI ≥30 kg/m²
Side Effects & Contraindications
Same class profile as semaglutide: nausea (most common), vomiting, constipation, pancreatitis (rare), thyroid C-cell tumor warning.
Contraindications:
- Personal/family history of MTC or MEN2
- Pregnancy
Legal & Regulatory Status
FDA approved (Victoza 2010, Saxenda 2014). EMA approved. Available globally.
Research Citations
- Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 (LEADER).
- Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 (SCALE).
- Davies MJ, et al. Liraglutide in Pediatric Obesity. N Engl J Med. 2021.